{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058636","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2026-05-11T20:05:35+00:00","discovered_at":"2026-05-11T20:07:00.351027+00:00","generated_at":"2026-05-11T22:48:33.659314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287","bullets":["Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.","Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.","MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.","Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.","New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058636","json":"https://secwatch.observer/filing/0001104659-26-058636.json","markdown":"https://secwatch.observer/filing/0001104659-26-058636.md","text":"https://secwatch.observer/filing/0001104659-26-058636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/0001104659-26-058636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/ganx-20260511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:48:33.659314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cf687328eef15d178d455c73dabb5ea7c73400d","claim":"Gain Therapeutics, Inc. reported first quarter ended March 31, 2026 results: EPS $0.13 per share, basic and diluted.","evidence_excerpt":"Net loss for the three months ended March 31, 2026, was $0.13 per share, basic and diluted, compared to $0.16 per share, basic and diluted, for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/0001104659-26-058636-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"EPS","value":"$0.13 per share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}